157 related articles for article (PubMed ID: 11394506)
21. New developments in the management of Waldenström macroglobulinemia.
Abeykoon JP; Yanamandra U; Kapoor P
Cancer Manag Res; 2017; 9():73-83. PubMed ID: 28331368
[TBL] [Abstract][Full Text] [Related]
22. Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.
Olszewski AJ; Treon SP; Castillo JJ
Oncologist; 2016 Nov; 21(11):1377-1386. PubMed ID: 27473042
[TBL] [Abstract][Full Text] [Related]
23. Waldenstrom macroglobulinemia: prognosis and management.
Oza A; Rajkumar SV
Blood Cancer J; 2015 Mar; 5(3):e394. PubMed ID: 25815903
[TBL] [Abstract][Full Text] [Related]
24. Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with Rituximab.
Pilarski LM; Baigorri E; Mant MJ; Pilarski PM; Adamson P; Zola H; Belch AR
Clin Med Oncol; 2008; 2():275-87. PubMed ID: 21892289
[TBL] [Abstract][Full Text] [Related]
25. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab.
Treon SP; Soumerai JD; Hunter ZR; Patterson CJ; Ioakimidis L; Kahl B; Boxer M
Blood; 2011 Jul; 118(2):276-81. PubMed ID: 21566092
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
Ansell SM; Kyle RA; Reeder CB; Fonseca R; Mikhael JR; Morice WG; Bergsagel PL; Buadi FK; Colgan JP; Dingli D; Dispenzieri A; Greipp PR; Habermann TM; Hayman SR; Inwards DJ; Johnston PB; Kumar SK; Lacy MQ; Lust JA; Markovic SN; Micallef IN; Nowakowski GS; Porrata LF; Roy V; Russell SJ; Short KE; Stewart AK; Thompson CA; Witzig TE; Zeldenrust SR; Dalton RJ; Rajkumar SV; Gertz MA
Mayo Clin Proc; 2010 Sep; 85(9):824-33. PubMed ID: 20702770
[TBL] [Abstract][Full Text] [Related]
27. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.
Vannucchi G; Campi I; Bonomi M; Covelli D; Dazzi D; Currò N; Simonetta S; Bonara P; Persani L; Guastella C; Wall J; Beck-Peccoz P; Salvi M
Clin Exp Immunol; 2010 Sep; 161(3):436-43. PubMed ID: 20529087
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.
Gertz MA; Abonour R; Heffner LT; Greipp PR; Uno H; Rajkumar SV
Br J Haematol; 2009 Dec; 147(5):677-80. PubMed ID: 19751237
[TBL] [Abstract][Full Text] [Related]
29. Rituximab in the treatment of non-Hodgkin's lymphoma.
Hauptrock B; Hess G
Biologics; 2008 Dec; 2(4):619-33. PubMed ID: 19707443
[TBL] [Abstract][Full Text] [Related]
30. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.
Treon SP; Ioakimidis L; Soumerai JD; Patterson CJ; Sheehy P; Nelson M; Willen M; Matous J; Mattern J; Diener JG; Keogh GP; Myers TJ; Boral A; Birner A; Esseltine DL; Ghobrial IM
J Clin Oncol; 2009 Aug; 27(23):3830-5. PubMed ID: 19506160
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.
Treon SP; Branagan AR; Ioakimidis L; Soumerai JD; Patterson CJ; Turnbull B; Wasi P; Emmanouilides C; Frankel SR; Lister A; Morel P; Matous J; Gregory SA; Kimby E
Blood; 2009 Apr; 113(16):3673-8. PubMed ID: 19015393
[TBL] [Abstract][Full Text] [Related]
32. Thalidomide and rituximab in Waldenstrom macroglobulinemia.
Treon SP; Soumerai JD; Branagan AR; Hunter ZR; Patterson CJ; Ioakimidis L; Briccetti FM; Pasmantier M; Zimbler H; Cooper RB; Moore M; Hill J; Rauch A; Garbo L; Chu L; Chua C; Nantel SH; Lovett DR; Boedeker H; Sonneborn H; Howard J; Musto P; Ciccarelli BT; Hatjiharissi E; Anderson KC
Blood; 2008 Dec; 112(12):4452-7. PubMed ID: 18713945
[TBL] [Abstract][Full Text] [Related]
33. Waldenstrom macroglobulinemia.
Leleu X; Roccaro AM; Moreau AS; Dupire S; Robu D; Gay J; Hatjiharissi E; Burwik N; Ghobrial IM
Cancer Lett; 2008 Oct; 270(1):95-107. PubMed ID: 18555588
[TBL] [Abstract][Full Text] [Related]
34. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N
Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560
[TBL] [Abstract][Full Text] [Related]
35. A SCID-hu in vivo model of human Waldenström macroglobulinemia.
Tassone P; Neri P; Kutok JL; Tournilhac O; Santos DD; Hatjiharissi E; Munshi V; Venuta S; Anderson KC; Treon SP; Munshi NC
Blood; 2005 Aug; 106(4):1341-5. PubMed ID: 15886318
[TBL] [Abstract][Full Text] [Related]
36. Waldenström macroglobulinemia.
Ghobrial IM; Witzig TE
Curr Treat Options Oncol; 2004 Jun; 5(3):239-47. PubMed ID: 15115652
[TBL] [Abstract][Full Text] [Related]
37. Innovative strategies in lymphoma therapy.
Jäger U
Wien Klin Wochenschr; 2003 Aug; 115(13-14):462-70. PubMed ID: 13677264
[TBL] [Abstract][Full Text] [Related]
38. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
39. CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.
Treon SP; Agus DB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother (1991); 2001 May; 24(3):272-279. PubMed ID: 11395644
[TBL] [Abstract][Full Text] [Related]
40. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
